The main objective of this pilot study is to obtain preliminary data on the reactivity of salivary oxytocin during a single LSD intake as part of PAP treatment for anxiety disorders or depression (treatment authorisations granted in advance by the Federal Officie of Public Health for compassionate use of the substance). There will be no interference with the usual clinical routine in our Service. The protocol is only for taking additional saliva measurements to measure oxytocin levels on the day of treatment. Participants will be asked to give 4 saliva samples the day of their LSD treatment .In addition they will fill-in self-report questionnaires which are part of the clinical routine
Study Type
OBSERVATIONAL
Enrollment
10
one single dose of LSD in the context of psychedelic assisted psychotherapy as a part of a clinical routine in our department
Geneva University Hospitals
Geneva, Switzerland
Salivary oxytocin
oxytocin sampled in the saliva
Time frame: the day of treatment administration (one day)
Self-reported symptoms of anxiety (STAI-T)
State-Trait Anxiety Inventory (trait), total scores ranging from 20 to 80, higher scores indicating higher anxiety
Time frame: over 6 months
Self-reported depressive symptoms (BDI-II)
Beck Depresion Inventory-II, total scores ranging from 0 to 63, higher scores indicating higher depressive symptoms
Time frame: over 6 months
Self-reported intensity of mystical experience
Assessed with the self-report Mystical experience Questionnaire (MEQ-30) with total man score ranging from 0 to 5, with higher scores indicating higher intensity of mystical experience
Time frame: The 1 day of treatment administration
Self-reported intensity of Connectedness
Assessed with the self-report Watts Connectedness Scale,total mean score ranging from 0 to 100, with higher scores indicating higher connectedess
Time frame: The 1 day of treatment administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.